Barclays raised the firm’s price target on Globus Medical (GMED) to $103 from $100 and keeps an Overweight rating on the shares. The company’s Q4 sales growth of 7% equates to low- to mid-teens underlying growth, the analyst tells investors in a research note. The firm says Globus’s record robot placements bode well for strong implant pull-through, suggesting the company’s 2025 outlook “is reasonable, if not conservative.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical’s Earnings Call: Record Revenue and Growth
- Globus Medical price target raised to $94 from $91 at BTIG
- Globus Medical’s Promising Outlook: Strong Financials, Strategic Acquisitions, and Continued Innovation Drive ‘Buy’ Rating
- Globus Medical price target lowered to $93 from $95 at Wells Fargo
- Buy Rating for Globus Medical Driven by Strong Financial Performance and Strategic Acquisitions